梅花生物(600873.SH)擬推2021年員工持股計劃 資金總額不超1.25億元
格隆匯1月14日丨梅花生物(600873.SH)披露2021年員工持股計劃(草案),本員工持股計劃的股份來源為公司回購專用賬户回購的股份,股份總數不超過5000萬股,佔公司目前股本總額的1.61%。
本員工持股計劃的參與對象為公司董事、監事、高級管理人員、獨立業務部門負責人。參加本員工持股計劃的總人數不超過210人,其中董事(不含獨立董事)、監事、高級管理人員為9人,具體參加人數根據員工實際繳款情況確定。本員工持股計劃購買回購股票的價格為2.50元/股,資金總額上限不超過1.25億元,以“份”作為認購單位,每份份額為1元,持股計劃的份額上限為1.25億份,員工必須認購整數倍份額。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.